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LETTERS TO THE EDITOR
Concerning the Fontan Patient’s Excessive
Minute Ventilation during Exercise
In their recent, insightful article concerning the cardiorespiratory
response to exercise following the Fontan procedure, Troutman et al.
(1) noted that patients with Fontan physiology tend to have elevated
DVE/DVCO2 during exercise. Although these authors acknowledged
that elevated VD/VT could account for this finding, they dismissed this
explanation in favor of a conjectured low chemoreceptor setpoint for
PaCO2. They considered the Fontan patients’ low-end tidal pCO2
measurements to be supportive of this latter hypothesis. They admit-
ted, however, that the mechanism by which the setpoint is lowered is
not readily apparent, and the mechanisms they proposed were rather
unsatisfying.
In contrast, ventilation/perfusion mismatch, secondary to the pul-
monary blood flow maldistribution that undoubtedly exists in the
Fontan patient’s nonpulsatile pulmonary circulation, could plausibly
account for the low end tidal pCO2, elevated VD/VT, and elevated
DVE/DVCO2. We have recently found evidence of that maldistribution
of pulmonary blood flow secondary to pulmonary artery stenoses,
which may cause similar ventilatory abnormalities during exercise in
patients with tetralogy of Fallot (2). Furthermore, on the basis of a few
reasonable assumptions and measurements similar to those employed
in Troutman’s study, we have generated estimates of VD/VT during
exercise and found that Fontan patients have significantly higher
VD/VT than do normal subjects and patients with tetralogy of Fallot
(3). Hence, we feel that pulmonary blood flow maldistribution, sec-
ondary to the absence of a pulmonary ventricle, is at the root of the
Fontan patient’s abnormal ventilatory pattern during exercise. This
explanation is compatible with the Fontan patient’s known cardiopul-
monary pathophysiology and seems to us much more plausible than
the speculation concerning an altered chemoreceptor setpoint.
P.S. Troutman et al. refer to an abrupt increase in PETCO2 as a
criterion for the determination of the anaerobic threshold (pg. 669,
second column, last line). Clearly they meant to say “PETO2.” You may
wish to publish this correction in a future issue.
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Reply
We thank Dr. Rhodes for his input regarding our interpretation of the
gas exchange data in Fontan patients during exercise. As pointed out
in our article, the two most likely explanations for excessive ventilation
are changes in chemoreceptor setpoint for PaCO2 and an increase in
VD/VT (deadspace ventilation). We clearly did not intend to dismiss
the latter as a possibility. Intuitively, increased physiologic deadspace,
secondary to ventilation-perfusion mismatches in Fontan patients with
prior thoracic surgery and laminar pulmonary blood flow, could
contribute to our findings. We welcome Dr. Rhodes’ interest in this
area and await the opportunity to examine his data. Our experiments
did not include invasive measurements of arterial oxygenation or other
techniques, which would have allowed direct calculation of VD/VT.
Until more direct measurements are made, or until improved, nonin-
vasive methods are developed, we will be dependent on indirect data
to explain the excessive ventilation during exercise found in these very
complex and diverse patients.
Finally, we thank Dr. Rhodes for pointing out the typographical
error regarding an increase in PETO2 not PETCO2 as an indicator for
identifying the respiratory anaerobic threshold.
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Lipoprotein (a): An Important Risk Factor in
Coronary Artery Disease
In most studies, the odds of coronary artery disease (CAD) have been
modest, usually 2 to 4, when the serum lipoprotein (a) [Lp(a)] level is
above 30 to 40 mg/dL using simple univariate analysis (1). This risk
nearly doubles when LDL is also elevated, with a corresponding
decrease in risk when the elevated LDL is lowered. This observation
has led many investigators to suggest that Lp(a) itself may not be an
important risk factor in the absence of elevated LDL (2). This
erroneous conclusion seems to have been reinforced by the Canadian
study by Cantin et al (3). They recommend that Lp(a) measurement
should not be carried out in primary prevention. We disagree with
their recommendations, because measurement of Lp(a) could identify
individuals at high risk of development of CAD as well as those who
benefit most from lipid-optimizing therapy.
Although Lp(a) was not an independent risk factor in French-
Canadians, others have found Lp(a) to be a powerful independent risk
factor in Germans (4), Swedes (5), and Americans (6). In the Canadian
study, the highest odds ratio for CAD for combined elevation of Lp(a)
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and total cholesterol was only 2.96. In contrast, a US study by Hopkins
et al (1) found an odds ratio for CAD of 13.8 (p 5 1.0 3 1027) for a
combination of Lp(a) .40 mg/dL and total cholesterol .260 mg/dL (a
fourfold higher value than that found by Cantin et al). The US study
involved 124 men and 46 women with premature CAD (,age 55 in
men and ,65 in women). CAD in all cases was documented by a
history of myocardial infarction, percutaneous transluminal coronary
angioplasty, or coronary artery bypass graft.
Many investigators have also neglected the interaction between
Lp(a) and other lipid and nonlipid CAD risk factors. In the US (1) the
presence of Lp(a) .40 mg/dL increased the risk associated with
cigarette smoking by a factor of 1.9, diabetes by a factor of 3.4, elevated
total cholesterol levels by a factor of 4.2, hypertension by a factor of
4.6, high total/HDL cholesterol ratio by a factor of 6.9, and high
homocysteine levels by a factor of 9.3. The presence of three or more
risk factors was associated with a relative risk of 43 (p , 0.0001) when
Lp(a) was .40 mg/dL, compared with a relative risk of 13 (p , 0.0001)
when Lp(a) was ,40 mg/dL.
Another striking finding in the US study (1) was the markedly
increased risk of CAD with elevated total/HDL cholesterol ratio.
Among those with Lp(a) .40 mg/dL, the odds ratio for CAD was 35
(p , 1.0 3 1027) when total/HDL cholesterol ratio was .5.8 versus
13.8 when total cholesterol level was .260 mg/dL. Among those with
high total/HDL cholesterol ratio and high Lp(a), the incremental risks
associated with additional coronary risk factors were more than
synergistic. For example, the odds ratio increased to 122 (p , 1.0 3
10212) in the combined presence of Lp(a) .40 mg/dL, total/HDL
cholesterol ratio of .5.8, and two or more nonlipid risk factors. For
comparison, in the Framingham Heart Study (7) the odds ratio for
CAD was only 20 when all the six risk factors, elevated cholesterol, low
HDL, diabetes, cigarette smoking, high blood pressure, and left
ventricular hypertrophy, were present. However, the odds ratio de-
creased to 1.3 when the total/HDL cholesterol ratio was ,5.8 and
other risk factors were absent, underscoring the importance of con-
comitant risk factors.
Solymoss et al. (8) have corroborated the crucial role of elevated
total/HDL ratio in markedly increasing the risk of CAD with elevated
Lp(a). They found a 100-fold risk of CAD in women when the
total/HDL cholesterol ratio was .5.8 and Lp(a) was .55 mg/dL versus
a total/HDL cholesterol ratio of ,4 and Lp(a) of ,15 mg/dL. These
data indicate that the CAD risk from elevated Lp(a) is greater with
elevated total/HDL cholesterol ratio than with elevated total choles-
terol. Since a high total/HDL cholesterol ratio is often due to low
HDL, those with elevated Lp(a) and low HDL cholesterol may be at
markedly increased risk of CAD, even if LDL is not excessively
elevated. Asian Indians appear to be such a population. They have the
highest rate of premature CAD, although they have low prevalence of
conventional risk factors, and nearly half of them are lifelong vegetar-
ians (9). Synergistic adverse effects of elevated Lp(a) with other
lipoproteins have been invoked to explain this excess burden of CAD
in Asian Indians (10). Elevated Lp(a) (.30 mg/dL) is found in 23–50%
of Asian Indians, but only 15% of Whites worldwide (11). Yet, the
population-attributable risk of premature CAD in the Framingham
Heart Study was similar to that of elevated total cholesterol (6).
However, this risk may vary in different populations since Lp(a) levels
vary markedly among people of different ethnic origin (10).
We have recently examined the association of Lp(a) and the
presence of chlamydia in coronary atherosclerosis in 60 autopsy
specimens (12). Of the 42 cases with severe atherosclerosis, 36 were
immunopositive for chlamydia, compared with 1 of 18 with mild
atherosclerosis (p , 0.001). Lp(a) levels were 19.9 6 4.4 mg/dL in
severe atherosclerosis versus 6.1 6 1.2 mg/dL in mild atherosclerosis
(p , 0.04). There was no correlation of the severity of atherosclerosis
with other lipids. In addition, we found that 48% of the cases with
severe atherosclerosis were positive for HLA class II genotype 13 or 17
as compared with 20% of cases with mild atherosclerosis (p , 0.01).
These results indicate a close association of Lp(a) abnormality with
chlamydia infection and certain genetic predisposition.
While we debate whether Lp(a) is an independent risk factor or
not, we should not lose sight of the fact that Lp(a) is a powerful and
important risk factor for CAD, particularly when total/HDL choles-
terol ratio is high. From a therapeutic perspective, niacin has been
shown to reduce the total/HDL ratio and Lp(a) levels by as much as
30% (13), with similar or greater reductions in LDL, when used in
combination with statins. Thus, in both primary and secondary pre-
vention, aggressive lipid-lowering therapy using a combination of
niacin and statins, aimed at lowering total/HDL ratio as well as LDL,
appears to be a viable strategy to reduce the markedly elevated risk
from elevated Lp(a), although evidence of benefit from randomized
clinical trials is yet to be reported.
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I am in total agreement with Drs. Enas and Mehta when they state that
lipoprotein (a) [Lp(a)] enhances the risk associated with other lipid
and nonlipid risk factors for ischemic heart disease. However, I do not
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